Anthropic Launches Claude for Healthcare, Waystar Shares Drop 8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Anthropic yesterday introduced Claude for Healthcare. The company said Claude for Healthcare "is a complementary set of tools and resources that allow healthcare providers, payers, and consumers to use Claude for medical purposes through HIPAA-ready products." Anthropic also added new capabilities for life sciences by connecting Claude "to more scientific platforms, and helping it provide greater support in areas ranging from clinical trial management to regulatory operations." Citi attributes the selloff in shares of Waystar Monday to the news from Anthropic. Waystar dropped 8% to $31.58 in late Monday trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAY
Wall Street analysts forecast WAY stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.450
Low
40.00
Averages
47.81
High
54.00
Current: 18.450
Low
40.00
Averages
47.81
High
54.00
About WAY
Waystar Holding Corp. provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. The Company’s enterprise-grade platform, Waystar, streamlines the complex processes. It leverages internally developed artificial intelligence (AI) as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers. Its software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. The Company’s clients utilize its software to manage pre-encounter workflows, such as eligibility checks and prior authorization approvals, as well as mid- and post-encounter workflows, such as co-pay collection, claims submission and monitoring, and payer remittances.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Leaders Show Strong Interest in AI-Powered Revenue Cycle Platform
- Industry Consensus: Waystar's 'State of the Mid-Revenue Cycle' report reveals unanimous interest among healthcare finance leaders in an AI platform connecting mid-cycle to final claims, yet 86% rely on manual data transfers, highlighting significant integration challenges in the sector.
- Efficiency Improvement Needs: The survey indicates that 82% of leaders struggle to keep pace with rapidly changing payer clinical policies, and 56% are dissatisfied with their ability to predict and prevent claim denials, underscoring the urgent need for more efficient solutions in revenue cycle management.
- Revenue Potential: Waystar's analysis shows that a connected, AI-powered mid-cycle can generate millions in incremental revenue for hospitals, improve quality scores, and reduce denial risks, emphasizing the critical importance of data integration.
- Strategic Recommendations: The report outlines five actionable strategies for organizations to enhance visibility, prevent revenue leakage earlier, and achieve stronger ROI, showcasing the transformative potential of AI platforms in healthcare payments.
See More
Waystar Releases New Report on Healthcare Revenue Cycle
- Industry Consensus: Waystar's 'State of the Mid-Revenue Cycle' report reveals that 86% of healthcare finance leaders lack true system integration and rely on manual data transfers, indicating a strong demand for a unified AI platform that could maximize revenue potential.
- Revenue Potential: The analysis shows that organizations fully leveraging Waystar's platform achieve an incremental reimbursement of $2.17 million per 10,000 discharges, with an 87% increase in Clinical Documentation Integrity (CDI) program impact, enhancing both financial returns and care quality.
- Conversion Rate Improvement: Providers using Waystar's advanced utilization management workflows see a 13% increase in observation-to-inpatient conversion rates, with an 82% accuracy in predicting inpatient status within the first hour of patient visits, effectively reducing medical necessity denial rates.
- Revenue Protection: Waystar's anomaly detection safeguards revenue before claims are generated, with early adopters unlocking up to $3 million in incremental revenue per 10,000 admissions, highlighting the critical role of real-time intelligence in revenue outcomes.
See More
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
Waystar CEO to Speak at 46th Annual William Blair Growth Stock Conference
- CEO Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 AM CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, underscoring its significance and influence in the industry.
- Transaction Processing Capacity: The company processes over 7.5 billion healthcare payment transactions annually, involving over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, demonstrating its critical role in healthcare payments.
See More
Waystar CEO to Speak at William Blair Conference
- Conference Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, showcasing its significant influence and market share in the healthcare sector.
- Transaction Processing Capacity: Annually, Waystar processes over 7.5 billion healthcare payment transactions, encompassing over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, underscoring its critical role in healthcare payments.
See More
Waystar Authorizes $200M Stock Repurchase Plan
- Stock Repurchase Plan: Waystar's board has authorized a stock repurchase plan of up to $200 million aimed at enhancing shareholder value through the buyback of common stock, although the plan does not obligate the company to acquire any specific amount of shares.
- Flexibility and Discretion: The repurchase plan allows the company to suspend or discontinue it at any time at its discretion, reflecting the company's flexibility in capital allocation and potential adjustments based on market conditions.
- Stable Revenue Guidance: Waystar projects its 2026 revenue to be between $1.274 billion and $1.294 billion, while adjusting its Q2 sequential growth outlook to flat to a 1% decline, indicating a cautiously optimistic view on future revenues.
- Market Reaction: While the repurchase plan may have a short-term positive impact on stock prices, the company's conservative revenue guidance could raise investor concerns about demand weakness, potentially affecting market confidence.
See More
Healthcare Leaders Show Strong Interest in AI-Powered Revenue Cycle Platform
- Industry Consensus: Waystar's 'State of the Mid-Revenue Cycle' report reveals unanimous interest among healthcare finance leaders in an AI platform connecting mid-cycle to final claims, yet 86% rely on manual data transfers, highlighting significant integration challenges in the sector.
- Efficiency Improvement Needs: The survey indicates that 82% of leaders struggle to keep pace with rapidly changing payer clinical policies, and 56% are dissatisfied with their ability to predict and prevent claim denials, underscoring the urgent need for more efficient solutions in revenue cycle management.
- Revenue Potential: Waystar's analysis shows that a connected, AI-powered mid-cycle can generate millions in incremental revenue for hospitals, improve quality scores, and reduce denial risks, emphasizing the critical importance of data integration.
- Strategic Recommendations: The report outlines five actionable strategies for organizations to enhance visibility, prevent revenue leakage earlier, and achieve stronger ROI, showcasing the transformative potential of AI platforms in healthcare payments.
See More
Waystar Releases New Report on Healthcare Revenue Cycle
- Industry Consensus: Waystar's 'State of the Mid-Revenue Cycle' report reveals that 86% of healthcare finance leaders lack true system integration and rely on manual data transfers, indicating a strong demand for a unified AI platform that could maximize revenue potential.
- Revenue Potential: The analysis shows that organizations fully leveraging Waystar's platform achieve an incremental reimbursement of $2.17 million per 10,000 discharges, with an 87% increase in Clinical Documentation Integrity (CDI) program impact, enhancing both financial returns and care quality.
- Conversion Rate Improvement: Providers using Waystar's advanced utilization management workflows see a 13% increase in observation-to-inpatient conversion rates, with an 82% accuracy in predicting inpatient status within the first hour of patient visits, effectively reducing medical necessity denial rates.
- Revenue Protection: Waystar's anomaly detection safeguards revenue before claims are generated, with early adopters unlocking up to $3 million in incremental revenue per 10,000 admissions, highlighting the critical role of real-time intelligence in revenue outcomes.
See More
Mid-Cap Healthcare Stocks Valuation Analysis
- Valuation Score Overview: According to Seeking Alpha's valuation grades, Acadia Healthcare Company (ACHC) and Waystar Holding (WAY) received an A rating, indicating their attractiveness relative to peers and suggesting potential investor interest for gains.
- Market Performance Highlights: Among mid-cap healthcare stocks with market capitalizations between $2B and $10B, BioCryst Pharmaceuticals (BCRX) stands out with a B+ valuation grade, reflecting its competitiveness and investment appeal in the biopharmaceutical sector.
- Valuation Metrics Analysis: The valuation scores are derived from a comprehensive analysis of multiple metrics, including P/E, PEG, EV/Sales, and EV/EBITDA, providing investors with a robust basis for informed investment decisions.
- Industry Trend Insights: As the healthcare sector continues to evolve, investor focus on mid-cap healthcare stocks is increasing, particularly those demonstrating strong valuation performance, which may attract greater investment inflows in the future.
See More
Waystar CEO to Speak at 46th Annual William Blair Growth Stock Conference
- CEO Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 AM CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, underscoring its significance and influence in the industry.
- Transaction Processing Capacity: The company processes over 7.5 billion healthcare payment transactions annually, involving over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, demonstrating its critical role in healthcare payments.
See More
Waystar CEO to Speak at William Blair Conference
- Conference Speaking Engagement: Waystar's CEO Matt Hawkins is scheduled to speak at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT, highlighting the company's leadership in healthcare payment software.
- Live Webcast Availability: The presentation will be available via live webcast on Waystar's Investor Relations website, ensuring global investors can access real-time updates and enhancing transparency and investor confidence.
- Extensive Client Base: Waystar serves over 30,000 clients, representing more than 1 million distinct providers, including 16 of the institutions listed in U.S. News Best Hospitals, showcasing its significant influence and market share in the healthcare sector.
- Transaction Processing Capacity: Annually, Waystar processes over 7.5 billion healthcare payment transactions, encompassing over $2.4 trillion in gross claims, covering approximately 60% of U.S. patients and one in three U.S. hospital discharges, underscoring its critical role in healthcare payments.
See More
Waystar Authorizes $200M Stock Repurchase Plan
- Stock Repurchase Plan: Waystar's board has authorized a stock repurchase plan of up to $200 million aimed at enhancing shareholder value through the buyback of common stock, although the plan does not obligate the company to acquire any specific amount of shares.
- Flexibility and Discretion: The repurchase plan allows the company to suspend or discontinue it at any time at its discretion, reflecting the company's flexibility in capital allocation and potential adjustments based on market conditions.
- Stable Revenue Guidance: Waystar projects its 2026 revenue to be between $1.274 billion and $1.294 billion, while adjusting its Q2 sequential growth outlook to flat to a 1% decline, indicating a cautiously optimistic view on future revenues.
- Market Reaction: While the repurchase plan may have a short-term positive impact on stock prices, the company's conservative revenue guidance could raise investor concerns about demand weakness, potentially affecting market confidence.
See More
